Vivaldi Biosciences

Executive Summary

Vivaldi Biosciences is a private biotech company developing self-adjuvanting nasal-spray vaccines for viral respiratory diseases based on its proprietary Delta NS1 platform. The lead candidate, DeltaFLU, is a universal influenza vaccine currently in Phase 2 clinical development, designed to provide broad protection against all influenza strains. The platform also supports a combination COVID-19 and universal influenza vaccine (Delta-19) in earlier development. Based in San Diego, the company leverages a differentiated mechanism that eliminates the need for external adjuvants and enables needle-free delivery, potentially improving patient compliance and public health outcomes. With Phase 2 data expected in the near term, Vivaldi represents an attractive opportunity in the vaccine space, particularly given the ongoing need for improved influenza vaccines and pandemic preparedness.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 DeltaFLU clinical trial results60% success
• Q2 2027Partnership or licensing deal for Delta NS1 platform40% success
• Q4 2026FDA regulatory feedback or meeting for DeltaFLU Phase 2/370% success